Journal of Addiction Medicine · 2015 · 10 citations · 1 references
MedicinePharmacologyPharmacotherapyNeuropharmacologyPsychopharmacologySubstance Use DisordersAddictionAddiction NeurobiologyAlcohol PharmacologyDrug DependencePharmacogenetic TestingPharmacogenomic TestingGenetic TestingGenetic Vulnerability To AddictionNmda Receptor SignalingNmda ReceptorsPharmacotherapy For Alcohol DependenceShared Genetic SusceptibilitySubstance Use Disorder GeneticsSubstance Use Genetics
Dextromethorphan, an antitussive (cough suppressant) drug of the morphinan class with sedative and dissociative properties found in cough syrup and other over-the-counter products, is also a substance of abuse, seen primarily in young adults all over the world. A case of dextromethorphan use disorder is presented in a 45-year-old women. Her repeated attempts at abstinence were unsuccessful secondary to continued intense cravings. Treatment with topiramate resulted in complete resolution of her cravings. Topiramate was chosen empirically because of a common action with dextromethorphan in the NMDA system. Genetic testing was obtained and the patient was found to be a carrier of the GRIK1 rs2832407(C:C) allele. The (C:C) allele has been associated with an increased risk of alcohol use disorder and a treatment response of patients with heavy drinking to topiramate. This case provides an opportunity to discuss personalized medicine (treatment options aided by the use of genetic testing) and the possible shared genetic susceptibility for dependence in 2 substances of abuse.
1